切换至 "中华医学电子期刊资源库"

中华医学超声杂志(电子版) ›› 2018, Vol. 15 ›› Issue (09) : 700 -706. doi: 10.3877/cma.j.issn.1672-6448.2018.09.011

所属专题: 文献

腹部超声影像学

肝动脉化疗栓塞联合射频消融治疗直径≥5 cm肝细胞癌患者10年疗效及预后分析
周洪雨1, 周燕1, 丁建民1, 王彦冬1, 于长路1, 经翔1,()   
  1. 1. 300170 天津市第三中心医院超声科;天津市肝胆疾病研究所;天津市人工细胞重点实验室;卫生部人工细胞工程技术研究中心
  • 收稿日期:2017-12-23 出版日期:2018-09-01
  • 通信作者: 经翔
  • 基金资助:
    天津市科学技术委员会(17ZXMFSY00050); 天津市卫生局重点课题(2014KR05)

Long term outcome of combining transarterial chemoembolization and radiofrequency ablation therapy for large hepatocellular carcinoma

Hongyu Zhou1, Yan Zhou1, Jianmin Ding1, Yandong Wang1, Changlu Yu1, Xiang Jing1,()   

  1. 1. Department of Ultrasound, the Third Central Hospital of Tianjin, Tianjin 300170, China
  • Received:2017-12-23 Published:2018-09-01
  • Corresponding author: Xiang Jing
  • About author:
    Corresponding author: Jing Xiang, Email:
引用本文:

周洪雨, 周燕, 丁建民, 王彦冬, 于长路, 经翔. 肝动脉化疗栓塞联合射频消融治疗直径≥5 cm肝细胞癌患者10年疗效及预后分析[J/OL]. 中华医学超声杂志(电子版), 2018, 15(09): 700-706.

Hongyu Zhou, Yan Zhou, Jianmin Ding, Yandong Wang, Changlu Yu, Xiang Jing. Long term outcome of combining transarterial chemoembolization and radiofrequency ablation therapy for large hepatocellular carcinoma[J/OL]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2018, 15(09): 700-706.

目的

探讨经导管肝动脉化疗栓塞(TACE)联合射频消融(RFA)治疗直径≥5 cm肝细胞癌(HCC)患者的远期疗效及预后影响因素。

方法

选择2006年1月至2015年12月天津第三中心医院收治并接受RFA治疗或RFA联合TACE治疗的HCC患者79例。其中36例HCC患者行单纯RFA治疗(RFA组),43例HCC患者行TACE联合RFA治疗(TACE联合组)。TACE联合组患者在TACE术后2周内进行RFA治疗。采用χ2检验比较TACE联合组与RFA组患者肿瘤首次完全消融率差异;采用Kaplan-Meier法对2组患者进行生存分析,并采用Log-rank检验比较2组患者的生存率。采用Cox回归分析直径≥5 cm的HCC患者预后的影响因素。

结果

TACE联合组患者肿瘤首次完全消融率93.0%(40/43),RFA组患者肿瘤首次完全消融率为91.7%(33/36),两者比较差异无统计学意义(χ2=0.051,P=0.821)。TACE联合组及RFA组患者1、3、5、7、10年肿瘤无进展生存率分别为78.8%、56.1%、38.4%、25.2%、16.8%及69.0%、40.0%、20.1%、13.4%、13.4%,两者差异无统计学意义(χ2=3.561,P=0.059);TACE组患者1、3、5、7、10年总生存率分别为83.4%、57.6%、45.9%、41.3%、31.0%,高于RFA组患者的68.8%、40.2%、24.1%、16.2%、16.2%,且差异有统计学意义(χ2=4.681,P=0.030)。单因素分析结果显示,合并门脉分支瘤栓、肿瘤无假包膜以及甲胎蛋白(AFP)浓度升高是影响直径≥5 cm的HCC患者总生存时间的因素;进一步多因素分析结果显示,合并门脉分支瘤栓及AFP浓度升高是影响直径≥5 cm的HCC患者总生存时间的独立危险因素。

结论

TACE联合RFA治疗能延长直径≥5 cm HCC患者的生存时间,改善患者预后;合并门脉分支瘤栓及AFP浓度是影响直径≥5 cm HCC患者预后的独立危险因素。

Objective

To investigate the long-term prognosis of patients with large hepatocellular carcinoma (HCC) receiving radiofrequency ablation (RFA) after transarterial chemoembolization (TACE) with patients treated by RFA alone and clarify the prognostic factors.

Methods

A total of 79 patients with a tumor more than 5 cm receiving combined treatment of RFA and TACE (43 patients) or RFA alone (36 patients) between January 2006 and December 2015 were enrolled in this study. Patients in the combined treatment group received RFA within two weeks after TACE. The complete ablation rates of two groups were compared using χ2 test. Survival analysis was conducted using Kaplan Meier methods. Log-rank examination was performed to compare the survival rate of the two groups. The prognostic factors were determined by Cox regression model.

Results

Complete response rates of the combined treatment group and the RFA alone group were 93% and 91.7%, respectively (χ2=0.051, P=0.821). The 1-, 3-, 5-, 7- and 10-year tumor progress-free survivals were 78.8%, 56.1%, 38.4%, 25.2% and 16.8% for the combined treatment group and 69.0%, 40%, 20.1%, 13.4% and 13.4% for the RFA alone group (χ2=3.561, P=0.059). The 1-, 3-, 5-, 7- and 10-year overall survivals in the combined treatment group were better than those in the RFA alone group (83.4%, 57.6%, 45.9%, 41.3%, 31.0% vs 68.8%, 40.2%, 24.1%, 16.2%, 16.2%, χ2=4.681, P=0.030). The univariate Cox proportional hazards regression model revealed a high level of AFP tumor embolus in portal vein and the tumor without a capsule were related to short overall survival. However, the multivariate analysis showed that only the first two factors were independent risk factors for overall survival.

Conclusion

Patients with a large HCC receiving RFA after TACE can get a better long-term prognosis compared with those receiving RFA alone. Patients with a high level of AFP and tumor embolus in portal vein were at the risk of poor prognosis.

表1 TACE联合组与RFA组患者一般临床资料比较
图2 射频消融治疗后可见消融区域完全覆盖并超出肿瘤碘油沉积区域,增强CT显示肿瘤完全消融
图5 超声造影引导下射频消融联合经皮无水乙醇注射治疗后,增强CT显示肿瘤三期无增强,病灶获得完全消融
图7 79例肝细胞癌患者生存曲线
图9 2组患者生存曲线比较
表2 直径≥5 cm的HCC患者预后的影响因素与赋值
表3 直径≥5 cm的HCC患者总生存时间的影响因素Cox回归单因素分析结果
表4 直径≥5 cm的HCC患者总生存时间的影响因素多因素分析
1
Yu J,Yu XL,Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial [J]. Gut, 2016, 66(6): 1172-1173.
2
Kim Y,Lim HK,Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors [J]. J Hepatol, 2013, 58(1): 89-97.
3
Livraghi T,Goldberg SN,Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions 1 [J]. Radiology, 2000, 214(3): 761-768.
4
Kokudo N,Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines [J]. J Gastroenterol, 2009, 44 Suppl 19: 119-121.
5
Ding J,Jing X,Liu J, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma [J]. Eur J Radiol, 2013, 82(9): 1379-1384.
6
Ding J,Jing X,Wang Y, et al. Thermal ablation for hepatocellular carcinoma: a large-scale analysis of long-term outcome and prognostic factors [J]. Clin Radiol, 2016, 71(12): 1270-1276.
7
Cheng BQ,Jia CQ,Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial [J]. JAMA, 2008, 299(14): 1669-1677.
8
Ni JY,Liu SS,Xu LF, et al. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma [J]. World J Gastroenterol, 2013, 19(24): 3872-3882.
9
Peng ZW,Zhang YJ,Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial [J]. J Clin Oncol, 2012, 31(4): 426-432.
10
高杰,朱继业. 卫生部《原发性肝癌诊疗规范(2011年版)》解读[J]. 中华普通外科杂志, 2012, 27(8): 693-695.
11
Hou YB,Chen MH,Yan K, et al. Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment [J]. World J Gastroenterol, 2009, 15(21): 2638-2643.
12
杨薇,陈敏华,严昆, 等. 射频消融对较大肝肿瘤治疗范围与布针方案计算的研究 [J]. 中华超声影像学杂志, 2002, 11(4): 244-247.
13
Ferlay J,Soerjomataram I,Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 136(5): E359-E386.
14
Torre LA,Bray F,Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108.
15
经翔,丁建民,王彦冬, 等. 超声引导下微波消融治疗肝脏恶性肿瘤328例并发症分析 [J/CD]. 中华医学超声杂志(电子版), 2011, 8(11): 2307-2313.
16
Forner A,Llovet JM,Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? [J]. J Hepatol, 2012, 56(4): 984-986.
17
杨家进,吴建兵. 原发性肝癌综合介入治疗进展 [J]. 实用肝脏病杂志, 2015, 18(2): 118-119.
18
Song MJ,Bae SH,Lee JS, et al. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma [J]. Korean J Intern Med, 2016, 31(2): 242-252.
19
Veltri A,Moretto P,Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC) [J]. Eur Radiol, 2006, 16(3): 661-669.
20
Dong W,Zhang T,Wang ZG, et al. Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis [J]. World J Gastroenterol, 2014, 20(29): 10174-10182.
21
Iezzi R,Pompili M,La Torre MF, et al. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma [J]. Dig Liver Dis, 2015, 47(3): 242-248.
22
Yang W,Yan K,Goldberg SN, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment [J]. World J Gastroenterol, 2016, 22(10): 2993-3005.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径<1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[6] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[7] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[8] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[9] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[10] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[11] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[12] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[13] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[14] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要